VitriVax Inc. has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.
VitriVax will apply its single-shot and thermostabilization technology (ALTA™) to the lead B. pseudomallei vaccine candidate, which is currently a three-dose regimen, with the goal of developing a single injection, thermostable vaccine formulation to protect against melioidosis and glanders.
The project will focus on preclinical studies and development of Good Manufacturing Practice protocols, working toward an Investigational New Drug Application submission.
“We are excited about the opportunity to partner with DTRA and researchers at the University of Nevada, Reno to bring our technology to a class of vaccines that will benefit both military personnel and the general population in regions where the disease is endemic,” said Kimberly D. Erickson, Ph.D., VitriVax’s Vice President of Operations and Principal Investigator.
VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA™) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines.